# EDGAR Filing Document

**Accession Number:** 0001697532
**File Stem:** 0001193125-25-288900
**Filing Date:** 2025-11
**Character Count:** 16582
**Document Hash:** 86642fbd52e0cbdbbd773f7142b5ec30
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-288900.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001193125-25-288900

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20251120

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Applied Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001697532
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38898
- **FILM NUMBER:** 251501035

**BUSINESS ADDRESS:**
- **STREET 1:** 545 FIFTH AVENUE, SUITE 1400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-220-9226

**MAIL ADDRESS:**
- **STREET 1:** 545 FIFTH AVENUE, SUITE 1400
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Applied Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20170208

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** November 20, 2025<br>

------

Applied Therapeutics, Inc.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-38898 | 81-3405262 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 545 Fifth Avenue, Suite 1400 |  |  |
| New York**,** New York |  | 10017 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** 212 220-9226<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.0001 | APLT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 8.01 Other Events.
Applied Therapeutics, Inc. (the "Company") has initiated a comprehensive review of strategic alternatives focused on maximizing shareholder value, including possible business combinations. The Company has not set a timetable for completion of this strategic review and does not intend to comment further on the status of this process unless or until its Board of Directors has approved a definitive course of action, or it is determined that other disclosure is appropriate. There can be no assurance that this strategic review will result in the Company pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms.

In connection with the evaluation of strategic alternatives, the Company is reducing the Company's workforce by approximately 46%, in addition to other cost-containment and cash conservation measures. The Company expects to substantially complete the reduction in its workforce by the end of the quarter ending December 31, 2025.

On November 20, 2025, the Company issued a press release announcing its plans to explore strategic alternatives. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Forward-Looking Statements**

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements regarding its ability to identify, assess and execute a strategic transaction, its planned workforce reduction and its ability to preserve cash as a result of such workforce reduction. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company's business are described in detail in its Securities and Exchange Commission ("SEC") filings, including in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which are available on the SEC's website at *www.sec.gov*. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law.

## Item 9.01 Financial Statements and Exhibits.
<br>**(d) Exhibits:** <br>

The following exhibit is attached with this current report on Form 8-K:

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| 99.1 | [<u>Press Release, dated November 20, 2025</u>](aplt-ex99_1.htm). |
| 104 | Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the inline XBRL document. |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **APPLIED THERAPEUTICS, INC.**  |
| Date: | November 20, 2025 | By:  | */s/ Les Funtleyder* |
|  |  |  | Les Funtleyder, Interim Chief Executive Officer and Chief Financial Officer |

---

------

## Exhibit 99.1

![img58575630_0.jpg](img58575630_0.jpg)

**Applied Therapeutics Announces Corporate Updates**

**NEW YORK, November 20, 2025** – Applied Therapeutics, Inc. (Nasdaq: APLT) (the "Company"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare diseases, today announced that Applied Therapeutics' Board of Directors (the "Board") has initiated a process to explore strategic alternatives for the Company.

The Board intends to evaluate a broad range of opportunities to maximize shareholder value. Strategic alternatives under consideration may include, but are not limited to, mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions.

The Board is committed to acting in the best interests of all stockholders. Consistent with its fiduciary duties and responsibilities, the Board will, in consultation with its financial and legal advisors, carefully evaluate and consider all options. The Company has not set a timetable for completion of the process for evaluating strategic alternatives. The Company does not intend to make any further public comment regarding the strategic review process unless and until it determines that further disclosure is appropriate or necessary. There is no assurance that this strategic review will result in a transaction or any other particular outcome.

In connection with the evaluation of strategic alternatives, the Company is reducing the Company's workforce by approximately 46%, in addition to other cost-containment and cash conservation measures.

"Our commitment to bringing govorestat to patients with rare diseases remains unwavering. To further advance this mission while maximizing value for shareholders, the Board has initiated a process to explore strategic alternatives designed to preserve our cash runway and ensure that we pursue the optimal path forward for all stakeholders. I want to sincerely thank our dedicated employees for their commitment to Applied, govorestat, patients and caregivers," said Les Funtleyder, interim CEO and CFO of Applied Therapeutics.

**Regulatory Update**

As previously announced, the Company completed a Type C meeting with the United States Food and Drug Administration (FDA) regarding govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency (CMT-SORD) in the third quarter of 2025. The Company is evaluating the official Type C meeting minutes and post-meeting written correspondence and expects to submit a request for an additional Type C meeting with the FDA with the intent of further discussing a potential Phase 3 trial design.

Additionally, the Company recently accepted written feedback from the FDA in connection with its planned meeting on the body of govorestat data submitted by the Company for Classic Galactosemia. The Company is evaluating the feedback with its advisors as it assesses next steps for the development of govorestat for the treatment of Classic Galactosemia. The Company may

------

pursue additional discussions with the FDA regarding a potential Phase 3 trial design at a later date.

**About Applied Therapeutics**

Applied Therapeutics is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. The Company's lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). To learn more, please visit www.appliedtherapeutics.com and follow the company on X at @Applied_Tx.

**Forward-Looking Statements**

This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding the strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," "predicts" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the Company's business, plans and outlook, (ii) our plans to explore strategic alternatives, including the timing and terms of any potential transaction, and our ability to identify a suitable third party and complete a transaction on acceptable terms, or at all, (iii) our plans to implement a corporate restructuring and workforce reduction, including the timing and scope of these events, and our ability to reduce cash burn as a result of these events, and (iv) expectations about the clinical development, regulatory strategy and commercialization of govorestat, including the potential for an NDA submission in CMT-SORD and potential eligibility for accelerated approval pathway, the timing and outcome of the upcoming meetings and other interactions with the FDA, the timing, design and readouts of our ongoing and clinical trials, including the potential Phase 3 trial in CMT-SORD and any other additional studies or trials that may be required by the FDA, and our development plans in Classic Galactosemia. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations or strategies will be attained or achieved.

Such risks and uncertainties include, without limitation, (i) our plans to pursue a strategic transaction and whether any transaction, if pursued, will be completed on attractive terms; (ii) our plans to develop, market and commercialize our product candidates, (iii) the initiation, timing, progress and results of our current and future preclinical studies and clinical trials and our research and development programs, (iv) our ability to take advantage of expedited regulatory pathways for any of our product candidates, (v) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing, (vi) our ability to successfully acquire or license additional product candidates on reasonable terms and advance product candidates into, and successfully complete, clinical studies, (vii) our ability to maintain and establish collaborations or obtain additional funding, (viii) our ability to obtain and timing of regulatory

------

approval of our current and future product candidates, (ix) the anticipated indications for our product candidates, if approved, (x) our expectations regarding the potential market size and the rate and degree of market acceptance of such product candidates, (xi) our ability to fund our working capital requirements and expectations regarding the sufficiency of our capital resources, including following our corporate restructuring, (xii) the implementation of our business model and strategic plans for our business and product candidates, (xiii) our intellectual property position and the duration of our patent rights, (xiv) developments or disputes concerning our intellectual property or other proprietary rights, (xv) our expectations regarding government and third-party payor coverage and reimbursement, (xvi) our ability to compete in the markets we serve, (xvii) the impact of government laws and regulations and liabilities thereunder, (xviii) developments relating to our competitors and our industry, (xix) our ability to achieve the anticipated benefits from the agreements entered into in connection with our partnership with Advanz Pharma and (xx) other factors that may impact our financial results. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including those described in the "Risk Factors" section contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

**Contacts**

**Investors:**

Julie Seidel / Andrew Vulis

(212) 600-1902

appliedtherapeutics@argotpartners.com

**Media:**

media@appliedtherapeutics.com

------